New Zealand markets closed

Kiniksa Pharmaceuticals, Ltd. (KNSA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
19.01+0.44 (+2.37%)
At close: 04:00PM EDT
19.65 +0.64 (+3.37%)
After hours: 05:13PM EDT
Show:
Income statement
Balance sheet
Annual

Cash flow

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Cash flows from operating activities
Net income
8,650
14,084
183,363
-157,924
-161,381
-
Depreciation & amortisation
2,211
2,341
2,402
2,355
2,405
-
Deferred income taxes
-30,500
-33,788
-185,495
11
4,361
-
Stock-based compensation
28,240
27,149
25,120
25,173
20,875
-
Change in working capital
9,668
1,350
-22,575
689
-4,315
-
Accounts receivable
-8,571
-8,606
-8,675
-3,910
0
-
Inventory
-3,853
-9,523
-17,924
-3,675
0
-
Accounts payable
4,193
347
6,031
1,366
-4,969
-
Other working capital
21,365
13,171
5,702
-146,713
-136,815
-
Other non-cash items
2,992
3,054
3,041
2,631
1,400
-
Net cash provided by operating activities
21,555
13,301
5,807
-126,298
-136,532
-
Cash flows from investing activities
Investments in property, plant and equipment
-190
-130
-105
-20,415
-283
-
Purchases of investments
-188,313
-204,933
-135,864
-157,250
-430,211
-
Sales/maturities of investments
222,390
175,506
127,800
306,300
407,050
-
Net cash used for investing activities
33,887
-29,557
-8,078
128,635
-23,444
-
Cash flows from financing activities
Common stock issued
-
-
3,417
0
228,222
83,106
Common stock repurchased
-2,167
-2,206
-901
0
0
-
Other financing activities
-
-
-
-
-1,136
-118
Net cash used provided by (used for) financing activities
5,018
1,495
2,516
5,885
227,086
-
Net change in cash
60,460
-14,761
245
8,222
67,110
-
Cash at beginning of period
80,618
122,715
122,470
114,248
47,138
-
Cash at end of period
141,078
107,954
122,715
122,470
114,248
-
Free cash flow
Operating cash flow
21,555
13,301
5,807
-126,298
-136,532
-
Capital expenditure
-190
-130
-105
-20,415
-283
-
Free cash flow
21,365
13,171
5,702
-146,713
-136,815
-